Williams Gregg purchased $2.0M of VANI (indirect holdings)

Williams Gregg purchased 1,587,301 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($2.00M total) on 2026-06-15.

Original reporting
SEC EDGAR · Williams Gregg
Published Jun 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VANI
Bullish
medium confidence
Mentioned
$VANI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VANIBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase size, price, and post-transaction holdings; it may marginally influence sentiment but does not change company fundamentals in the text.

02

Market read

Traders may view the filing as a small bullish signal, but it is unlikely to drive a sustained repricing without accompanying operational news.

03

What to watch

The purchase is indirect and the article provides no context on prior holdings, motivation, or whether other insiders/large holders are acting similarly.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-16; purchase dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Vivani Medical, Inc.

Company-level read

Ticker impact

$VANIBullishMedium confidence
Context

SEC Form 4 shows Vivani Medical director/10% owner Williams Gregg bought 1,587,301 shares of VANI on 2026-06-15.

Expected impact

Likely minimal near-term price impact; may slightly support sentiment if market treats it as bullish.

Evidence & confidence

The filing is primary-source and specific, but Form 4 insider buys are often routine and not a new operating catalyst.

Market effects

No sector-wide read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A director/10% owner buy can be driven by diversification, liquidity needs, or pre-planned trading rather than a new bullish thesis (notably, no 10b5-1 plan is cited).

Key entities

  • Vivani Medical, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Williams Gregg

    Director and 10% owner who reported an indirect open-market purchase of VANI shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VANILow

Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight manageme

$VANIMedAI 8/10

Vivani reports phase 1 trial results for semaglutide implant

Vivani Medical (NASDAQ:VANI) reported Phase 1 trial results for NPM-139, a semaglutide implant for weight management. The trial showed no adverse events in the NPM-139 group, with similar weight loss to Wegovy. Vivani plans to advance to Phase 2 trials in 2027 and explore development in new patient groups. The company collaborates with Novo Nordisk on the technology.

$VANIMed

Vivani Medical Merger Closing Awaits Final Regulatory Approval

Vivani Medical's merger with Cortigent awaits final regulatory approval, with closing expected shortly after. The deal will make Cortigent a subsidiary of ClearOne. Vivani had initially targeted an October 2026 closing, but the timeline is now uncertain. The transaction may not be completed due to regulatory or other issues, according to the company.

$VANIMed

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana

$VANIMed

Vivani Flat on Hookup with Novo

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.